{"id":"W3167608264","doi":"10.1200/jco.2021.39.15_suppl.8011","title":"Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Carfilzomib; Minimal residual disease; Lenalidomide; Dexamethasone; Oncology; Internal medicine; Multiple myeloma; Autologous stem-cell transplantation; Interim analysis; Clinical endpoint; Phases of clinical research; Chemotherapy; Clinical trial; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005029192,0.001074993,0.00134787,0.0002772924,0.0003077762,0.0008944162,0.0006606609,0.0008413334,0.003846196],"category_scores_gemma":[0.003247395,0.0003523276,0.001580202,0.0002310317,0.0004265078,0.0006709369,0.0005699144,0.001954558,0.0005677392],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004527949,"about_ca_system_score_gemma":0.0010266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003535239,"about_ca_topic_score_gemma":0.0009804626,"domain_scores_codex":[0.9988594,0.0007049699,0.00003982436,0.0001022377,0.00006910428,0.0002245807],"domain_scores_gemma":[0.9978228,0.000786701,0.0005053233,0.0002259083,0.00008249842,0.000576748],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9130078,0.01280435,0.01184439,0.0003158781,0.002381785,0.0003706048,0.0001314189,0.006497345,0.006482791,0.0003180401,0.009715659,0.03612986],"study_design_scores_gemma":[0.5087417,0.4030775,0.05828683,0.00006743608,0.00391901,0.0006254834,0.00008935951,0.009687917,0.005970513,0.001658744,0.007806365,0.00006909021],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866434,0.00146677,0.00160612,0.0008840697,0.0002437891,0.00182277,0.003839019,0.0001792969,0.003314812],"genre_scores_gemma":[0.9862955,0.0003156578,0.002219696,0.0009913523,0.0001278237,0.002211925,0.005543607,0.00004285144,0.002251561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005029192,"threshold_uncertainty_score":0.0265972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2087677462614769,"score_gpt":0.5099627723187464,"score_spread":0.3011950260572696,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}